Entering text into the input field will update the search result below

Glaukos' iStent shows long-term benefit in glaucom study

Dec. 11, 2018 4:48 PM ETGlaukos Corporation (GKOS) StockBy: Douglas W. House, SA News Editor
  • Glaukos (NYSE:GKOS) announces positive results from a multiyear single-site study evaluating the iStent inject Trabecular Micro-Bypass System, combined with cataract surgery, in glaucoma patients. The data were just published in the journal Ophthalmology and Therapy.
  • After three years of follow-up, treated patients achieved a 37% reduction in mean intraocular pressure while mean medication burder dropped 68%.
  • 93% of treated patients were able to reduce their medications. 54% of eyes were medication-free.

Recommended For You

More Trending News

About GKOS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GKOS--
Glaukos Corporation